Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2019-11-14 Interim / Quarterly Rep…
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Pharmena_Skonsolidowany raport za III kwartał 2019
Interim / Quarterly Report Classification · 100% confidence The document is a detailed table of contents for a 'Skonsolidowany Raport Kwartalny' (Consolidated Quarterly Report) for the period ending September 30, 2019. It includes comprehensive financial statements (balance sheet, cash flow, income statement) and detailed management notes, which confirms it is an interim/quarterly report rather than a simple announcement or summary. 9M 2019
2019-11-14 Polish
Zmiana terminu publikacji raportu za III kwartał 2019 roku - Content (PL)
Report Publication Announcement Classification · 99% confidence The document text explicitly states that the publication date for the Q3 2019 report is being changed ('ulega zmianie termin publikacji raportu za III kwartał 2019 roku'). It announces a new date (November 14, 2019) for the Q3 2017 report (though the context seems to mix up years, the core action is announcing a change in reporting schedule) and mentions that future changes will be announced via a current report. This is an announcement about the timing of a financial report release, not the report itself. This fits the definition of a Report Publication Announcement (RPA). The document is very short (919 chars), supporting the 'MENU VS MEAL' rule suggesting it's an announcement rather than the full report (IR or 10-K).
2019-10-18 Polish
190930_PHR_oswiadczenie zarządu_wybór audytora_1H2019
Audit Report / Information Classification · 98% confidence The document is titled "OŚWIADCZENIE ZARZĄDU W SPRAWIE PODMIOTU UPRAWNIONEGO DO BADANIA SPRAWOZDAŃ FINANSOWYCH" (Management Statement Regarding the Entity Authorized to Audit Financial Statements). The text explicitly states that the Management Board has selected the auditing firm for the semi-annual condensed individual and consolidated financial statements for the first half of 2019, confirming compliance with independence and ethical standards. This content directly relates to the audit process and the auditor's qualifications, fitting the definition of an Audit Report / Information (AR), which covers applied accounting principles and results of internal/regulatory stress tests, or in this case, the formal selection/statement regarding the audit itself. It is not a full 10-K, an earnings release (ER), or a presentation (IP). Since it is a formal statement concerning the audit process, AR is the most appropriate classification. H1 2019
2019-09-30 Polish
190930_PHR_oswiadczenie zarządu_rzetelność_1H2019
Regulatory Filings Classification · 95% confidence The document is a formal 'Oświadczenie Zarządu' (Management Statement) certifying the accuracy of the financial statements for the first half of 2019. It does not contain the actual financial statements, tables, or substantive financial data required for an Interim Report (IR). Per the 'Certification Rule', documents that are primarily officer certifications or attestations regarding financial reports should be classified as Regulatory Filings (RNS). H1 2019
2019-09-30 Polish
PHARMENA Raport z przegladu 30.06.2019-sig-sig
Audit Report / Information Classification · 99% confidence The document is titled "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO SPRAWOZDANIA FINANSOWEGO" (Independent Auditor's Review Report on the Condensed Interim Financial Statements). It explicitly covers the financial statements for the period ending June 30, 2019, and references International Accounting Standard 34 (Interim Financial Reporting). This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year, which corresponds to the Interim / Quarterly Report category (IR). Although it is an audit/review report, the primary subject matter is the interim financial statements themselves, making IR more specific than AR (which is for standalone audit reports excluding full annual reports, but IR covers interim comprehensive reports). Given the detailed financial components listed (statement of financial position, statement of comprehensive income, etc.) for a half-year period, IR is the best fit. H1 2019
2019-09-30 Polish
GK PHARMENA Raport z przegladu 30.06.2019-sig-sig
Audit Report / Information Classification · 99% confidence The document is explicitly titled "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO SKONSOLIDOWANEGO SPRAWOZDANIA FINANSOWEGO" (Independent Auditor's Report on the Review of the Interim Condensed Consolidated Financial Statements). This clearly indicates it is a report detailing the results of an audit or review process on financial statements, specifically for an interim period (ending June 30, 2019). This aligns perfectly with the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinguishing it from a full Annual Report (10-K) or a comprehensive Interim Report (IR) which would contain the statements themselves, not just the auditor's opinion on them. The document contains the auditor's conclusion ('Wniosek') based on a review conducted according to specific standards (KSRF 2410 / ISRE 2410). H1 2019
2019-09-30 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.